Sovaldi (sofosbuvir)

Sovaldi (sofosbuvir)Sovaldi (sofosbuvir) – General Information (PDF)

Targeted Genotype: 1 – 4 (Genotype 4 Health Canada approved but not covered by BC PharmaCare)

Approvals: Please see the Sovaldi Treatment Combinations section below for more information.

Treatment Description: Sovaldi (sofosbuvir) is a nucleotide NS5B polymerase inhibitor. Nucleotide NS5B polymerase inhibitors are used in combination with other treatments to directly target the hep C virus and stop it from making copies of itself in the liver.

Usage Warning: Patients with bradycardia taking amiodarone can not take Sovaldi (sofosbuvir) in any combination.

Sovaldi Treatment Combinations

Genotype Sovaldi (sofosbuvir) Treatment Combination Approved by Health Canada for use in Canada
Covered by BC PharmaCare
2, 3 Sovaldi + Ribavirin (RBV) Yes Yes
1 Galexos (simeprevir) + Sovaldi Yes No
*The treatment combinations that are covered by BC PharmaCare are only done so as limited coverage drugs. Harvoni and Epclusa also include Sovaldi, however, they aren’t considered combinations for the purposes of this table because they are single pill treatments that can’t be broken down into their two parts.

See Hep C Drug Pipeline Treatments for information about Sovaldi (sofosbuvir) combinations not covered by BC PharmaCare.

Sovaldi Treatment Combinations that are BC PharmaCare Covered

Treatment Patients # of Weeks
Sovaldi with ribavirin (RBV) Genotype 2 patients who have and have never tried treatment with no liver cirrhosis or with compensated cirrhosis 12
Sovaldi with RBV Patients with genotype 3 and treatment-naïve and treatment- experienced with or without compensated cirrhosis 24

BC PharmaCare Eligibility for Sovaldi-Based Treatments

For the treatment of treatment naïve or treatment-experienced adult patients with chronic hepatitis C (CHC) genotype 2 or 3 infection who meet ALL of the following criteria:

  1. Treatment is prescribed by a hepatologist, a gastroenterologist, an infectious disease specialist or other physicians experienced with treating hepatitis C
  2. Laboratory confirmed hepatitis C genotype 2 or 3
  3. Laboratory confirmed quantitative HCV RNA test must be done within the last 12 months
  4. Patient is NOT currently being treated with another hepatitis C direct-acting antiviral drug (with the exception of daclatasvir for genotype 3)
  5. Fibrosis stage of  F2 or greater (Metavir scale or equivalent); OR

Fibrosis stage less than F2 (Metavir scale or equivalent) AND at least one of the following:

  • Co-infection with HIV or hepatitis B virus
  • Post organ transplant (liver and/or non-liver organ transplant)
  • Extra-hepatic manifestations
  • Chronic kidney disease stage 3, 4 or 5 as defined by National Kidney Foundation Kidney Disease outcomes Quality Initiative
  • Co-existent liver disease with diagnosis evidence for fatty liver disease (e.g., non-alcoholic steatohepatitis)
  • Diabetes receiving treatment with anti-diabetic drugs
  • Women who are planning pregnancy within the next 12 months

Talk to your healthcare provider for more information or to start the treatment process.

Gilead’s Momentum Patient Assistance Program

Canadians prescribed Sovaldi (sofosbuvir) have the opportunity to request to be enrolled in the Gilead Momentum Program. For more information, contact your doctor, nurse, or call the Gilead Momentum Program at: 1-855-447-7977. One can also find more information about the assistance program by clicking the above link and then scrolling down the page.